17 completed, 14 terminated, 4 withdrawn, 3 active not recruiting. 27 Phase 2, 20 Phase 1, 2 Phase 3.
Follow INCB039110: new trials by email Literature Review of INCB039110 trials Research Report on INCB039110
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2022-12-29 | 2026-10-14 |
| Itacitinib for the Prevention of Graft Versus Host Disease Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematologic and Lymphocytic Disorder | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2022-01-11 | 2026-10-07 |
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) ASTX727, Itacitinib, Ruxolitinib - MDS/MPN | Phase 1 / Phase 2 | Recruiting | Michael Savona | 94 | 2021-11-24 | 2026-10-29 |
| Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Itacitinib, Itacitinib Adipate - Bronchiolitis Obliterans | Phase 1 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-10-08 | 2025-11-10 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) itacitinib - Myelofibrosis, Polycythemia Vera | Phase 2 | Completed | Incyte Corporation | 4 | 2021-07-12 | 2025-09-02 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Itacitinib, Extracorporeal Photopheresis (ECP) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | University of Utah | 3 | 2021-01-29 | 2024-01-22 |
| Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Fludarabine - Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-09-22 | 2020-10-29 | |
| A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Itacitinib, Immune effector cell therapy, Placebo - Cytokine Release Syndrome | Phase 2 | Completed | Incyte Corporation | 112 | 2020-02-07 | 2024-03-26 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2020-01-15 | 2024-10-10 |
| Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Itacitinib, Corticosteroids - Acute Graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 2 | 2019-12-31 | 2025-11-04 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Trametinib, Dabrafenib, INCB039110 - Melanoma | Phase 1 | Terminated | Massachusetts General Hospital | 1 | 2019-05-29 | 2023-09-22 |
| Itacitinib + Everolimus in Hodgkin Lymphoma Itacitinib, Everolimus - Classical Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Pennsylvania | 23 | 2019-02-11 | 2026-06-23 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Itacitinib, Placebo, Methylprednisolone - Chronic Graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | Incyte Corporation | 155 | 2019-01-17 | 2025-10-20 |
| Itacitinib in Advanced Hepatocellular Carcinoma Itacitinib - Advanced Hepatocellular Carcinoma | Phase 1 | Completed | Imperial College London | 19 | 2018-12-03 | 2026-05-04 |
| A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Itacitinib, Placebo - Moderate to Severe Ulcerative Colitis | Phase 2 | Withdrawn | Incyte Corporation | 2018-09-20 | 2019-12-06 | |
| Relieving Chronic Itch: Oral Medication INCB039110 - Pruritis | Phase 2 | Withdrawn | Washington University School of Medicine | 2018-08-01 | 2019-05-13 | |
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer Itacitinib, Pembrolizumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | University of Pennsylvania | 23 | 2018-06-18 | 2023-09-13 |
Showing 20 of 40. Sign in to see all of them.
Primary Myelofibrosis (5) · Bronchiolitis Obliterans Syndrome (4) · Carcinoma, Non-Small-Cell Lung (4) · Graft vs Host Disease (4) · Myeloproliferative Disorders (4) · Hematologic Neoplasms (3) · Bronchiolitis Obliterans (2) · Hematologic Diseases (2) · Hodgkin Disease (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1) · Arthritis, Rheumatoid (1)
Incyte Corporation (27) · M.D. Anderson Cancer Center (4) · University of Pennsylvania (2) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Imperial College London (1) · Massachusetts General Hospital (1) · Michael Savona (1) · University of Utah (1) · Washington University School of Medicine (1)
United States (34) · Spain (7) · Italy (6) · Austria (5) · Belgium (5) · Canada (5) · Germany (5) · France (4) · United Kingdom (4) · Greece (3) · Israel (3) · Poland (3) · Australia (2) · Finland (2) · South Korea (2)
Rodica Morariu-Zamfir, MD (6) · Peter Langmuir, MD (4) · Lance Leopold, MD (2) · Peter Langmuir (2) · Victor Sandor, MD (2) · Albert Assad, M.D. (1) · Albert Assad, MD (1) · Amin Alousi, MD (1) · Amit Pande, M.D. (1) · Brian Kim, MD/MTR (1) · Catherine Lee, MD (1) · Claudia Corrado, M.D. (1) · Corey Langer, MD (1) · David M. Miller, MD, PhD (1) · Ekaterine Asatiani, M.D. (1)
PMID 35689489, PMID 27789678, PMID 29695516, PMID 30115734, PMID 30803990, PMID 32324888, PMID 32998963, PMID 34971577, PMID 35288468, PMID 38115208, PMID 40090005, PMID 41536780
2017 (5), 2018 (2), 2019 (1), P30CA033572 (1)